Sign in
Taking peoplePhase 2

Low-dose interleukin-2 for several long-lasting inflammatory barrier diseases

Tests low-dose interleukin-2 in pemphigus, pemphigoid, myositis or primary sclerosing cholangitis.

Key facts

Who runs it
Universitaetsklinikum Schleswig-Holstein AöR
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID)
Status
Recruiting
Phase
Phase 2
People taking part
112 people, planned
Started
27 Dec 2024
Expected to end
1 Apr 2027
Type of study
Interventional
Record updated
15 January 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with one of four active long-term inflammatory diseases: pemphigus vulgaris or foliaceus, mucous membrane pemphigoid, polymyositis or dermatomyositis, or primary sclerosing cholangitis (PSC). It tests low-dose IL-2 against a placebo.

Age
18 to 80 years
Sex
All sexes
Disease stage
Pemphigus: mild to moderate activity, PDAI score ≥ 6 and ≤ 45. Mucous membrane pemphigoid: mild to moderate activity, MMPDAI score ≥ 6 and ≤ 45. Polymyositis or dermatomyositis: other rheumatic diseases at the same time are allowed. PSC: inflammatory bowel disease at the same time is allowed.
Biomarker or test result
Polymyositis or dermatomyositis: blood creatine kinase (CK) of ≥ 300 U/L and ≤ 3000 U/L. PSC: blood alkaline phosphatase (AP) at least 1.5 times the upper limit of normal.

Main reasons for not taking part

  • Serious damage to a vital organ
  • A life-threatening disease
  • Long-lasting active infections

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants with pemphigus vulgaris / foliaceus (PV/PF) and having mild to moderate disease activity as defined by a PDAI ≥ 6 and ≤ 45
  • Participants with mucous membrane pemphigoid (MMP) and having mild to moderate disease activity as defined by a MMPDAI of ≥ 6 and ≤ 45
  • Participants with polymyositis (PM) or dermatomyositis (DM) and having elevated plasma concentrations of the creatine kinase (CK) of ≥ 300 U/L and ≤ 3000 U/L. Concomitant diagnoses of other rheumatic diseases (overlaps) are allowed
  • Participants with primary sclerosing cholangitis (PSC) and having elevated plasma concentrations of the alkaline phosphatase (AP) of ≥ 1.5 times above the upper limit of normal. Concomitant diagnosis of inflammatory bowel diseases is allowed
  • Age of participants: ≥ 18 years and ≤ 80 years

Who cannot take part

  • Severe impairment of vital organ or life-threatening disease
  • Chronically active infectious diseases

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective of this exploratory, indication-finding basket trial is to evaluate and compare the safety and the relationship between the magnitude of Treg responses and clinical responses elicited by low-dose IL-2 therapy in participants with active Pemphigus vulgaris / foliaceus (PV/PF), Mucous Membrane Pemphigoid (MMP), Polymyositis/ Dermatomyositis (PM/DM) and Primary Sclerosing Cholangitis (PSC).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID): a single-center, randomized, double-blind and placebo-controlled phase 2 clinical basket trial
Plain-language title
Low-dose interleukin-2 for several long-lasting inflammatory barrier diseasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
15 January 2025